

# AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine



Jumpstart your week with a deep dive into the future of medicine as part of Goodwin's exclusive programming during the BIO International Convention in Boston. Join us for a dynamic symposium where industry leaders and AI pioneers come together to unveil how artificial intelligence is revolutionizing drug discovery. Don't miss this chance to explore groundbreaking technologies and connect with the minds shaping tomorrow's healthcare.

RSVP [here](#) to attend and see below for more details!

**Date & Time:** Monday June 16 from 1:00 PM - 4:30 PM ET

**Location:** Goodwin's Boston Office, 100 Northern Avenue. Boston, MA 02210

**1:00 - 1:30 PM** | Registration & Lunch

**1:30 - 2:00 PM** | Panel: AI Governance and AI Security

- Kaitlin Betancourt, Partner, Goodwin
- Jud Welle, Partner, Goodwin
- Tom Doughty, Chief Information Security Officer, Generate:Biomedicines

**2:05 - 2:40 PM** | Panel: Diligence Considerations with Tech Acquirers and IP Risks from AI in Drug Discovery and Development

- Marty Gomez, Partner, Goodwin
- Sarah Solomon, Partner, Goodwin
- Robert Carroll, Partner, Goodwin
- Hilary Eaton, CBO, Profluent
- Jen Asher, PhD, Founder and CEO, 1910 Genetics

**2:40 - 3:00 PM** | Networking/Coffee Break

**3:00 - 3:30 PM** | Fireside Chat: Advancing a New Era of Programmable Biology Through AI

- Joe Theis, Partner, Goodwin
- Mike Nally, CEO, Generate:Biomedicines

**3:35 - 3:45 PM** | FDA Insights on AI in Drug Development

- Qi Liu, Co-Chair of CDER AI Council; Lead of CDER AI Review Rapid Response Team, U.S.

Food and Drug Administration (*virtual*)

**3:50 - 4:30 PM** | Panel: Smarter Drug Development - The Role of AI in Regulatory Strategy

- Julie Tibbets, Partner, Goodwin
- Alexander Morgan, MD, PhD, Partner, Khosla Ventures
- Tracey Sikora, Vice President of Research & Clinical Programs of the National Organization for Rare Disorders (NORD); Co-Founder of Every Cure